LEPL The First University Clinic of Tbilisi State Medical University
Tbilisi, Georgia
2 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Systemic Sclerosis
Boehringer Ingelheim448 enrolledNCT07497087
Recruiting
Phase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled296 locationsNCT07220083
Recruiting
Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled225 locationsNCT06226883
Recruiting
Phase 2
Confirmatory Clinical Study in Active Ulcerative Colitis
Colitis Ulcerative
MRM Health NV204 enrolled16 locationsNCT07296315
Recruiting
Phase 1
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
Chronic Obstructive Pulmonary Disease
Bambusa Therapeutics286 enrolled14 locationsNCT06944925
Recruiting
Phase 3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Neutropenia
X4 Pharmaceuticals176 enrolled114 locationsNCT06056297
Recruiting
Phase 3
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
GERD (Gastroesophageal Reflux Disease)
Cinclus Pharma Holding AB500 enrolled75 locationsNCT07037875
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135